157 related articles for article (PubMed ID: 21565516)
21. Synthesis, oral bioavailability determination, and in vitro evaluation of prodrugs of the antiviral agent 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA).
Starrett JE; Tortolani DR; Russell J; Hitchcock MJ; Whiterock V; Martin JC; Mansuri MM
J Med Chem; 1994 Jun; 37(12):1857-64. PubMed ID: 8021925
[TBL] [Abstract][Full Text] [Related]
22. 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl] cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine with improved therapeutic index in vivo.
Bischofberger N; Hitchcock MJ; Chen MS; Barkhimer DB; Cundy KC; Kent KM; Lacy SA; Lee WA; Li ZH; Mendel DB
Antimicrob Agents Chemother; 1994 Oct; 38(10):2387-91. PubMed ID: 7840575
[TBL] [Abstract][Full Text] [Related]
23. Synthesis of LAVR-289, a new [(Z)-3-(acetoxymethyl)-4-(2,4-diaminopyrimidin-6-yl)oxy-but-2-enyl]phosphonic acid prodrug with pronounced antiviral activity against DNA viruses.
Bessières M; Roy V; Abuduani T; Favetta P; Snoeck R; Andrei G; Moffat J; Gallardo F; Agrofoglio LA
Eur J Med Chem; 2024 May; 271():116412. PubMed ID: 38643669
[TBL] [Abstract][Full Text] [Related]
24. Synthesis, anti-HBV activity and renal cell toxicity evaluation of mixed phosphonate prodrugs of adefovir.
Fu XZ; Ou Y; Pei JY; Liu Y; Li J; Zhou W; Lan YY; Wang AM; Wang YL
Eur J Med Chem; 2012 Mar; 49():211-8. PubMed ID: 22305613
[TBL] [Abstract][Full Text] [Related]
25. Aryl ester prodrugs of cyclic HPMPC. I: Physicochemical characterization and in vitro biological stability.
Oliyai R; Shaw JP; Sueoka-Lennen CM; Cundy KC; Arimilli MN; Jones RJ; Lee WA
Pharm Res; 1999 Nov; 16(11):1687-93. PubMed ID: 10571273
[TBL] [Abstract][Full Text] [Related]
26. Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines.
De Clercq E; Andrei G; Balzarini J; Leyssen P; Naesens L; Neyts J; Pannecouque C; Snoeck R; Ying C; Hocková D; Holý A
Nucleosides Nucleotides Nucleic Acids; 2005; 24(5-7):331-41. PubMed ID: 16247948
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and antiviral activity of the nucleotide analogue (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine.
Bronson JJ; Ghazzouli I; Hitchcock MJ; Webb RR; Martin JC
J Med Chem; 1989 Jul; 32(7):1457-63. PubMed ID: 2544723
[TBL] [Abstract][Full Text] [Related]
28. Acyclic nucleoside phosphonates in the chemotherapy of DNA virus and retrovirus infections.
De Clercq E
Intervirology; 1997; 40(5-6):295-303. PubMed ID: 9675635
[TBL] [Abstract][Full Text] [Related]
29. Ester prodrugs of acyclic nucleoside thiophosphonates compared to phosphonates: synthesis, antiviral activity and decomposition study.
Roux L; Priet S; Payrot N; Weck C; Fournier M; Zoulim F; Balzarini J; Canard B; Alvarez K
Eur J Med Chem; 2013 May; 63():869-81. PubMed ID: 23603046
[TBL] [Abstract][Full Text] [Related]
30. PMPA and PMEA prodrugs for the treatment of HIV infections and human papillomavirus (HPV) associated neoplasia and cancer.
Pertusati F; Hinsinger K; Flynn ÁS; Powell N; Tristram A; Balzarini J; McGuigan C
Eur J Med Chem; 2014 May; 78():259-68. PubMed ID: 24686012
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic potential of Cidofovir (HPMPC, Vistide) for the treatment of DNA virus (i.e. herpes-, papova-, pox- and adenovirus) infections.
De Clercq E
Verh K Acad Geneeskd Belg; 1996; 58(1):19-47; discussion 47-9. PubMed ID: 8701600
[TBL] [Abstract][Full Text] [Related]
32. In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): differences between acyclovir and penciclovir?
Andrei G; De Clercq E; Snoeck R
Antiviral Res; 2004 Mar; 61(3):181-7. PubMed ID: 15168799
[TBL] [Abstract][Full Text] [Related]
33. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art.
Hostetler KY
Antiviral Res; 2009 May; 82(2):A84-98. PubMed ID: 19425198
[TBL] [Abstract][Full Text] [Related]
34. Synthesis, in vitro antiviral evaluation, and stability studies of bis(S-acyl-2-thioethyl) ester derivatives of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability.
Benzaria S; Pélicano H; Johnson R; Maury G; Imbach JL; Aubertin AM; Obert G; Gosselin G
J Med Chem; 1996 Dec; 39(25):4958-65. PubMed ID: 8960556
[TBL] [Abstract][Full Text] [Related]
35. Conversion of 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine to cidofovir by an intracellular cyclic CMP phosphodiesterase.
Mendel DB; Cihlar T; Moon K; Chen MS
Antimicrob Agents Chemother; 1997 Mar; 41(3):641-6. PubMed ID: 9056007
[TBL] [Abstract][Full Text] [Related]
36. In vitro activity of potential anti-poxvirus agents.
Kern ER
Antiviral Res; 2003 Jan; 57(1-2):35-40. PubMed ID: 12615301
[TBL] [Abstract][Full Text] [Related]
37. Transporter-targeted lipid prodrugs of cyclic cidofovir: a potential approach for the treatment of cytomegalovirus retinitis.
Gokulgandhi MR; Barot M; Bagui M; Pal D; Mitra AK
J Pharm Sci; 2012 Sep; 101(9):3249-63. PubMed ID: 22499243
[TBL] [Abstract][Full Text] [Related]
38. Comparative study of the anti-human cytomegalovirus activities and toxicities of a tetrahydrofuran phosphonate analogue of guanosine and cidofovir.
Bedard J; May S; Lis M; Tryphonas L; Drach J; Huffman J; Sidwell R; Chan L; Bowlin T; Rando R
Antimicrob Agents Chemother; 1999 Mar; 43(3):557-67. PubMed ID: 10049267
[TBL] [Abstract][Full Text] [Related]
39. Synthesis of cidofovir and (S)-HPMPA ether lipid prodrugs.
Beadle JR
Curr Protoc Nucleic Acid Chem; 2007 Jun; Chapter 15():Unit 15.2. PubMed ID: 18428972
[TBL] [Abstract][Full Text] [Related]
40. In vitro evaluation of the anti-orf virus activity of alkoxyalkyl esters of CDV, cCDV and (S)-HPMPA.
Dal Pozzo F; Andrei G; Lebeau I; Beadle JR; Hostetler KY; De Clercq E; Snoeck R
Antiviral Res; 2007 Jul; 75(1):52-7. PubMed ID: 17184854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
